Wound Closure Device with Monomeric Antihypertensive Coating
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current wound closure devices often result in significant scarring, which can lead to adverse medical and psychological effects, and existing anti-scarring methods may not effectively minimize scar formation during the healing process due to slow release rates and potential for unwanted distribution of therapeutic agents.
Innovation Solution
A wound closure device incorporating a monomeric antihypertensive agent, such as captopril, which is applied in a biodegradable coating to facilitate rapid release and localized anti-scarring effects, reducing collagen deposition and fibrosis, thereby minimizing scar tissue formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polymer coatings are used to control release of bioactive agents, then the release can be controlled, but the release rate becomes slow and unwanted distribution may occur
Solution Approach 1:
The patent changes the molecular structure parameter of the antihypertensive agent from polymer form to monomer form. This parameter change enables rapid release while maintaining controlled delivery, as monomers can diffuse quickly through the biodegradable coating matrix without the slow degradation kinetics associated with polymer forms.
Solution Approach 2:
The patent applies the antihypertensive agent locally at the wound site through a biodegradable coating on the wound closure device. This localized application ensures the therapeutic agent acts precisely where needed during healing, minimizing unwanted distribution to other body regions while maintaining controlled release characteristics.
2Object-generated harmful factors
If surgical revision techniques are used to treat scars, then scar tissue can be removed, but patients experience additional trauma and psychological aversion
Solution Approach 1:
The patent converts the harmful effect of scar formation into a beneficial outcome by applying anti-scarring therapy during the primary wound closure. The monomeric antihypertensive agent inhibits collagen deposition and fibrosis, transforming what would be a harmful scarring process into a controlled healing process that minimizes scar tissue formation without requiring subsequent surgical revision.
Solution Approach 2:
The patent performs preliminary anti-scarring action during the primary wound closure by incorporating the antihypertensive agent into the wound closure device. This preliminary treatment prevents excessive collagen deposition and fibrosis before scar tissue can fully develop, eliminating or reducing the need for later surgical revision procedures.
3Speed
If monomeric antihypertensive agents are used, then rapid release is achieved, but the anti-scarring effect duration is limited
Solution Approach 1:
The patent ensures continuous anti-scarring action by designing the biodegradable coating to maintain release of the monomeric antihypertensive agent throughout the critical wound healing period. The coating degrades continuously, providing sustained therapeutic concentrations that prevent collagen deposition and fibrosis throughout the entire healing process, not just during initial rapid release.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device achieves rapid and localized anti-scarring effects by ensuring the antihypertensive agent is released during the wound healing process, minimizing scar formation and reducing the risk of unwanted distribution, thus enhancing the healing outcome.
Implementation Method 1
A wound closure device incorporating a monomeric antihypertensive agent, such as captopril, which is applied in a biodegradable coating to facilitate rapid release and localized anti-scarring effects
Data Source
Figure 1~2A
Figure 2B
Figure 3A~3B
AI summary
The present invention relates to a medical device (10; 20; 30; 40), preferably wound closure device, comprising a device body (12; 22; 32; 42), in particular an elongate device body, and a monomeric antihypertensive agent. The invention further relates to a method for manufacturing such a device (10; 20; 30; 40).